clinical trial · NCT05533372
MAD Study of IA-14069
ILAb Co., Ltd.·phase1·recruiting·n = 75
HealthyRheumatoid ArthritisIA-14069PlaceboMethotrexateMethotrexate
brief summary
The purpose of this study is to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple ascending oral doses of IA-14069 in healthy subjects and in patients with RA on stable dosese of MTX, with preliminary assessment of efficacy in RA patients.
started
Oct 10, 2022
primary completion
Nov 1, 2025
completion
Feb 1, 2026
last updated
May 20, 2025
official title
Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IA-14069 in Healthy Subjects, With an Extension to Explore Any Drug-Drug Interaction Potential With Methotrexate (Part 1), and in Patients With Rheumatoid Arthritis, With Preliminary Assessment of Efficacy in Patients (Part 2)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol